AKBA Q1 2025 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$365M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$57M+75.8% YoY

Gross Profit

$50M86.7% margin

Operating Income

$14M23.6% margin

Net Income

$6M10.7% margin

EPS (Diluted)

$0.03

QoQ Revenue Growth

+23.3%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$310M

Total Liabilities

$286M

Stockholders' Equity

$25M

Cash & Equivalents

$113M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$57M	$33M	+75.8%
Gross Profit	$50M	$30M	+66.3%
Operating Income	$14M	-$15M	+190.5%
Net Income	$6M	-$18M	+134.0%

Revenue Segments

Product

$56M97%

License Collaboration And Other Revenue

$2M3%